Breakthroughs in these areas may be attributed to the maturation of liver-targeted delivery systems (e.g., GalNAc coupling technology), which have made metabolic disorders (e.g., PCSK9 targeting) more amenable to efficient gene silencing. This evidence concerns the gene PCSK9 and Other metabolic disease.